STOCK TITAN

Aldeyra Therapeu Stock Price, News & Analysis

ALDX Nasdaq

Welcome to our dedicated page for Aldeyra Therapeu news (Ticker: ALDX), a resource for investors and traders seeking the latest updates and insights on Aldeyra Therapeu stock.

Aldeyra Therapeutics (ALDX) is a clinical-stage biotechnology company developing innovative therapies targeting diseases mediated by toxic aldehydes, with active programs in ocular inflammation and systemic immune disorders. This page provides investors and industry professionals with comprehensive access to Aldeyra's official announcements, including clinical trial updates, regulatory milestones, and strategic partnerships.

Key resources include real-time updates on product candidates like reproxalap for dry eye disease, filings with regulatory agencies, and research collaborations. Users gain a centralized hub to track the company's progress in addressing conditions such as noninfectious anterior uveitis and metabolic disorders through its novel aldehyde sequestration platform.

Regular updates cover Phase clinical results, FDA communications, intellectual property developments, and scientific presentations. The curated news feed enables efficient monitoring of Aldeyra's pipeline advancements and market positioning within the precision medicine landscape.

Bookmark this page for direct access to verified ALDX disclosures and analysis essential for evaluating the company's therapeutic innovations and investment potential.

Rhea-AI Summary

Aldeyra Therapeutics (Nasdaq: ALDX), a clinical-stage biotech firm focused on immune-mediated and metabolic diseases, announced that CEO Todd C. Brady will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event, featuring a discussion with Jefferies' SVP Kelly Shi, is scheduled for 3:30 p.m. ET on June 5, 2024. The company specializes in developing RASP modulators like reproxalap and ADX-2191 for treating conditions such as dry eye disease and retinitis pigmentosa. Webcast details are available on Aldeyra's website, with the session archived for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.37%
Tags
conferences
-
Rhea-AI Summary

Aldeyra Therapeutics has enrolled the first patient in a Phase 3 clinical trial for reproxalap in treating dry eye disease, aiming for a potential NDA resubmission by the second half of 2024. The company expects positive results to lead to an NDA resubmission to the FDA, incorporating acute and chronic improvements in symptoms and ocular redness. The planned review period for the resubmission is six months, with promising preliminary data from previous trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.17%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.05%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
-
-

FAQ

What is the current stock price of Aldeyra Therapeu (ALDX)?

The current stock price of Aldeyra Therapeu (ALDX) is $4 as of July 2, 2025.

What is the market cap of Aldeyra Therapeu (ALDX)?

The market cap of Aldeyra Therapeu (ALDX) is approximately 210.2M.
Aldeyra Therapeu

Nasdaq:ALDX

ALDX Rankings

ALDX Stock Data

210.23M
53.14M
2.44%
63.08%
6.05%
Biotechnology
Pharmaceutical Preparations
Link
United States
LEXINGTON